We launched Pairnomix in 2016 to help people with a rare genetic disease live a better life.
One of the most exciting developments in the study of rare diseases is genetic sequencing. As important as it is to identify the genetic mutation responsible for an individual’s mutation, that’s only the beginning. Pairnomix picks up where sequencing leaves off and translates this knowledge into therapeutic solutions, both for individual patients today as well as for larger populations in the future.
Our personalized screening services are offered to patients and physicians impacted by a rare genetic disorder. These services involve creating a laboratory model of an individual’s genetic mutation, evaluating the mutation’s functional consequence, and testing more than 1,300 on-market drugs against the modeled mutation. As a result, we can identify new drugs that are available today and may be effective for the individual’s rare genetic condition.
Our drug discovery and development work leverages insights obtained through our personalized screening service along with internally-focused discovery efforts. We seek to identify drug candidates that could be reformulated or repurposed for the treatment of rare genetic disease and also explore the design of novel compounds.
While we have begun our work within the rare genetic neurological disease setting, we plan to expand our services and the indications we evaluate. We hope to provide valuable results to a variety of people as we pursue our mission of empowering individuals living with rare genetic conditions, as well as the physicians who treat them.
Matthew Fox, CEO